LorenK.MellMD

Gynecologic Cancer, Head & Neck

Professor of Radiation Medicine Vice Chair, Clinical and Translational Research Director, Center for Precision Radiation Medicine UC San Diego Medical Center

Join to view full profile

Dr. Mell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mell's full profile

Already have an account?

Office
3855 Gilman Dr
Dept Ucsd
La Jolla, CA 92093
Phone+1 858-822-6040

Fax+1 858-822-6080

Summary

Dr. Loren Mell is a radiation oncologist in La Jolla, CA and is affiliated with multiple hospitals in the area, including VA San Diego Healthcare System and UC San Diego Health. He received his medical degree from University of Chicago Pritzker School of Medicine and has been in practice 14 years. He specializes in gynecologic cancer and head & neck and is experienced in image-guided radiation therapy.

Education & Training

University of Chicago/University of Illinois College of Medicine at ChicagoResidency, Radiation Oncology, 2004 - 2008
Ascension Illinois/ResurrectionInternship, Transitional Year, 2003 - 2004
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003

Certifications & Licensure

CA State Medical License 2008 - 2026
IL State Medical License 2003 - 2008
American Board of Radiology Radiation Oncology

Clinical Trials

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Start of enrollment: 2012 Jun 18
Completed
Phase 3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer Start of enrollment: 2011 Oct 13
COMPLETED
PHASE2, PHASE3
Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma Start of enrollment: 2010 Aug 01
Completed
Phase 1
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer Start of enrollment: 2012 Apr 01
Completed
Phase 1
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. Start of enrollment: 2013 Mar 15
Completed
Phase 2
Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB Start of enrollment: 2017 Jun 02
Withdrawn
Phase 2
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Start of enrollment: 2018 Apr 03
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer Start of enrollment: 2018 Mar 15
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

Redefining Candidates for Deintensification in Locoregionally Advanced P16+ Oropharyngeal Cancer Based on Relative Risk.
Ryan T Morse, Tyler J Nelson, Hannah C Liu, Prangrawee Sangchan, Bhargava Chitti
International Journal of Radiation Oncology, Biology, Physics. 2025-03-01
NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025.
A Dimitrios Colevas, Anthony J Cmelak, David G Pfister, Sharon Spencer, Douglas Adkins
Journal of the National Comprehensive Cancer Network. 2025-02-01
1 citations
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial.
Jyoti Mayadev, Dmitriy Zamarin, Wei Deng, Heather A Lankes, Giulio Pesci
Nature Communications. 2025-01-09

Journal Articles

‘Optimism Bias’ in Contemporary National Clinical Trial Network Phase III Trials: Are We Improving?
S S Noticewala, L K Mell, Annals of Oncology

Lectures

Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisp...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t an OptionDecember 19th, 2024
Radiotherapy with Adjuvant Durvalumab No Benefit for Head, Neck CancerDecember 10th, 2024
There's a Best Option for Patients with Head-and-Neck Cancer Who Can't Take CisplatinNovember 26th, 2024
Join now to see all